Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFLECT: Real-time targeted fluorescence endoscopy for detection of the primary cancer lesion in head and neck metastasis of unknown primary
2024-513897-23-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by University Medical Center Groningen. Primary endpoints: Macroscopic fluorescent signal levels and tracer distribution observed with targeted fluorescence endoscopy (TFE) and Detection rates of targeted fluorescence endoscopy (TFE) and white light endoscopy (WLE). Planned start Nov 2024; status: authorised.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-513897-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513897-23-00.